Everything below concerns AOD9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Fatigue === Fatigue is a common symptom of fibromyalgia. Patients may experience physical or mental fatigue. Physical fatigue can present as a feeling of exhaustion after exercise or limitation in daily activities. Fibromyalgia fatigue can range from feeling mildly tired to flu-like exhaustion. Severe fatigue may come on suddenly, making it difficult to be active at all. The impact of fatigue can be severe and pose more of a problem than the pain. Fatigue is a complicated, multifactorial, and vexing symptom that is highly prevalent (76%) and stubbornly persistent, as evidenced by longitudinal studies over 5 years. Fatigue does not improve with sleep or rest. Medication seems to have little impact on FM fatigue.
== History == Dexamethasone was first synthesized by Philip Showalter Hench in 1957. It was introduced for medical use in 1958. On 16 June 2020, the RECOVERY Trial announced preliminary results stating that dexamethasone improves survival rates of hospitalized patients with COVID-19 receiving oxygen or on a ventilator. Benefits were only observed in patients requiring respiratory support; those who did not require breathing support saw a worse survival rate than the control group, although the difference may have been due to chance. A preprint containing the full dataset was published on 22 June 2020, and demand for dexamethasone surged after the publication of the preprint. The preliminary report was published in The New England Journal of Medicine on 18 July 2020. The final report was published in February 2021. The World Health Organization (WHO) states that dexamethasone should be reserved for seriously ill and critical patients receiving COVID-19 treatment in a hospital setting, and the WHO Director-General stated that "WHO emphasizes that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm." In July 2020, the WHO stated they were in the process of updating treatment guidelines to include dexamethasone or other steroids. In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19.
== Legal and judicial figures == Richard Harison (1764), first U.S. attorney for the District of New York Peter van Schaack (1767), loyalist and attorney Abraham Van Vechten (1780s), two-time New York attorney general Anthony Bleecker (1791), lawyer and founding member of the New-York Historical Society Samuel Jones Jr. (1793), recorder of New York City; chancellor of New York; chief justice of the New York City Superior Court Augustus B. Woodward (1793), first chief justice of the Michigan Territory; one of the founders of the University of Michigan Thomas Phoenix (1795), New York County district attorney Pierre C. Van Wyck (1795), New York County district attorney; recorder of New York City William P. Van Ness (1797), judge on the United States District Court for the Southern District of New York Sampson Simson (1800), attorney, philanthropist, remembered as the "father of Mount Sinai Hospital" Alexander Hamilton Jr. (1804), son of Alexander Hamilton, attorney, soldier, and member of the New York State Assembly Hugh Maxwell (1808), New York County district attorney and Collector of the Port of New York Matthew C. Paterson (1809), New York County district attorney Ogden Hoffman (1812), former New York State attorney general, U.S. attorney for the Southern District of New York, and U.S. congressman from New York Frederic de Peyster (1819), New York attorney Theodore Sedgwick III (1829), U.S. attorney for the Southern District of New York Samuel Blatchford (1837), associate justice of the U.S.
== Early life and education == Coon was born in Mount Pleasant, Michigan. He earned his B.Sc. from Central Michigan University in 1998, and received his Ph.D. from the University of Florida in 2002, where he worked with Willard Harrison.
Sources: en.wikipedia.org
==== 10 Man Operational Ration Pack ==== The UK also fields a larger pack of rations intended to feed ten soldiers for 24 hours from centralised but basic preparation; generally similar in content to the single issue ORP but tending to contain larger quantities of food in cylindrical tin cans to be divided up on preparation, rather than individual retort pouches or packets. Even dry materials like sugar or biscuits are often packed in these cans. They contain ingredients for baking bread and tinned food, including vegetables, corned beef and sausages in lard. Also included are chocolate, pre-cooked chicken or beef in gravy and soya mince. Ten boxed one-man ORPs are supplied in larger boxes identical in shape to the single ten-man pack.
== References == Butler, Rohan, MA., Bury, J.P.T., MA., & Lambert M.E., MA., editors, Documents on British Foreign Policy 1919–1939, 1st Series, Her Majesty's Stationery Office, London, 1960, vol. x, Chapter VIII, "The Plebiscites in Allenstein and Marienwerder January 21 – September 29, 1920" Keynes, John Maynard. A Revision of the Treaty: Being a Sequel to The Economic Consequences of the Peace, Harcourt, Brace, 1922 Kossert, Andreas. Masuren: Ostpreussens vergessener Süden, ISBN 3-570-55006-0 (in German) Mayer, S. L., MA. History of the First World War – Plebiscites:Self Determination in Action, Peter Young, MA., editor, BPC Publishing Ltd., UK., 1971. Rhode, Gotthold. Die Ostgebiete des Deutschen Reiches, Holzner-Verlag Würzburg, 1956. Tooley, T. Hunt. National Identity and Weimar Germany: Upper Silesia and the Eastern Border, 1918–1922, U of Nebraska Press, 1997, ISBN 0-8032-4429-0 Topolski, Jerzy. An Outline History of Poland, Interpress, 1986, ISBN 83-223-2118-X Wambaugh, Sarah. Plebiscites since the World War, Washington DC, 1933. I pp 99–141; II pp 48–107 Williamson, David G. The British in Germany 1918–1930, Oxford, 1991, ISBN 0-85496-584-X
ribonuclease (RNase) Any of a class of nuclease enzymes which catalyze the hydrolytic cleavage of phosphodiester bonds in RNA molecules, thus severing polymeric strands of ribonucleotides into smaller components. Compare deoxyribonuclease.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.